基于挪威健康登记数据的观察性数据模拟试验NCT04754594评估妊娠期BNT162b2 mRNA COVID-19疫苗有效性
本研究利用挪威全国健康登记数据模拟随机对照试验NCT04754594,评估妊娠期接种BNT162b2 mRNA COVID-19疫苗的有效性。纳入2021年1月1日后孕24周且2022年11月30日前分娩的5790例妊娠(2895例接种首剂,2895例未接种)。意向性治疗分析显示感染风险降低20%(IRR 0.80,95%CI 0.48-1.13),符合方案分析显示降低39%(IRR 0.61,95%CI 0.27-0.95),与试验结果(风险降低41%)相当。SARS-CoV-2相关住院因结局罕见无法评估。
要点
- 意向性治疗分析中疫苗接种与感染风险降低20%相关(IRR 0.80,95%CI 0.48-1.13)。
- 符合方案分析中疫苗接种与感染风险降低39%相关(IRR 0.61,95%CI 0.27-0.95)。
- 该模拟试验与随机对照试验NCT04754594结果在统计学上满意对齐。
核心结论
- 该试验模拟显示与随机对照试验NCT04754594结果在统计学上满意对齐,支持使用观察性数据评估妊娠人群疫苗有效性。
研究设计与样本
- 利用挪威全国健康登记数据模拟随机对照试验NCT04754594,纳入2021年1月1日后孕24周且2022年11月30日前分娩的妊娠。
- 接种组在孕24-34周接种首剂,意向性治疗分析假设21天内接种第二剂,符合方案分析要求实际接种第二剂。
- 采用倾向性评分按孕周序贯匹配接种组与同期未接种组,协变量包括基线特征和末次月经日期。
主要发现
- 共纳入5790例妊娠,其中接种组2895例,未接种组2895例。
- 未接种组平均母亲年龄31.1岁(SD 4.3),接种组31.4岁(SD 4.6)。
- 未接种组平均BMI 24.7(SD 4.6),接种组24.9(SD 5.0)。
- 意向性治疗分析显示疫苗接种与感染风险降低20%相关(IRR 0.80,95%CI 0.48-1.13)。
- 符合方案分析显示疫苗接种与感染风险降低39%相关(IRR 0.61,95%CI 0.27-0.95),与试验的风险降低41%相当。
关键数值与推荐
- 意向性治疗分析:感染风险IRR 0.80(95%CI 0.48-1.13)。
- 符合方案分析:感染风险IRR 0.61(95%CI 0.27-0.95)。
- 随机对照试验NCT04754594报告的风险降低为41%。
临床怎么用
- 原文未据此给出推荐。
局限性
- SARS-CoV-2相关住院因在人群中结局罕见而无法评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous observational studies of mRNA COVID-19 vaccine effectiveness in pregnancy differ from the randomized trial NCT04754594, limiting causal inference. Using nationwide Norwegian health registry data, we emulated trial NCT04754594 to assess agreement of point estimates for BNT162b2 vaccine effectiveness in pregnancy. We included pregnancies reaching gestational week 24 after January 1, 2021, and delivering before November 30, 2022. Vaccinated individuals received a first dose between weeks 24-34 of gestation, with a second dose assumed within 21 days (intention-to-treat, ITT); the as-treated (AT) analysis required second-dose administration. We sequentially matched vaccinated individuals by gestational week to those who remained unvaccinated until the same gestational week, using propensity scores based on baseline covariates and last menstrual period date. Outcomes were SARS-CoV-2 infection and SARS-CoV-2-related hospitalization until one month post-delivery. Among 5790 pregnancies (2895 first dose-vaccinated, 2895 unvaccinated), mean maternal ages were 31.1 years (SD 4.3) in the unvaccinated, and 31.4 years (SD 4.6) vaccinated group. Mean BMI was 24.7 (SD 4.6) and 24.9 (SD 5.0), respectively. The ITT analysis showed that vaccination was associated with a 20 % lower risk of infection (IRR: 0.80, 95 % CI: 0.48, 1.13); the AT analysis showed a 39 % lower risk (IRR: 0.61, 95 % CI: 0.27, 0.95), comparable to that of the trial (41 % risk reduction). SARS-CoV-2-related hospitalizations could not be evaluated due to the rarity of the outcome in our population. This trial emulation demonstrated satisfactory statistical alignment with trial results, supporting the use of observational data to assess vaccine effectiveness in pregnant populations.
引用
- Zidan M, Trinh NTH, Desalegn A, et al. BNT162b2 mRNA COVID-19 vaccine effectiveness in pregnancy: Emulating trial NCT04754594 using observational data from Norwegian health registries. Vaccine. 2025. PMID: 41202612. doi:10.1016/j.vaccine.2025.127908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。